Difference between revisions of "Systemic mastocytosis"
(added regimen) |
|||
Line 188: | Line 188: | ||
# Casassus P, Caillat-Vigneron N, Martin A, Simon J, Gallais V, Beaudry P, Eclache V, Laroche L, Lortholary P, Raphaël M, Guillevin L, Lortholary O. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol. 2002 Dec;119(4):1090-7. [http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2002.03944.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12472593 PubMed] | # Casassus P, Caillat-Vigneron N, Martin A, Simon J, Gallais V, Beaudry P, Eclache V, Laroche L, Lortholary P, Raphaël M, Guillevin L, Lortholary O. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol. 2002 Dec;119(4):1090-7. [http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2002.03944.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12472593 PubMed] | ||
# '''Retrospective:''' Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009 Dec;84(12):790-4. [http://onlinelibrary.wiley.com/doi/10.1002/ajh.21561/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19890907 PubMed] | # '''Retrospective:''' Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009 Dec;84(12):790-4. [http://onlinelibrary.wiley.com/doi/10.1002/ajh.21561/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19890907 PubMed] | ||
+ | |||
+ | ==Midostaurin (Rydapt) {{#subobject:99c398|Regimen=1}}== | ||
+ | {{#subobject:e08d5d|Variant=1}} | ||
+ | {{:Midostaurin (Rydapt) for aggressive systemic mastocytosis}} | ||
==Nilotinib (Tasigna) {{#subobject:91cff9|Regimen=1}}== | ==Nilotinib (Tasigna) {{#subobject:91cff9|Regimen=1}}== | ||
Line 216: | Line 220: | ||
==IWG-MRT & ECNM consensus response criteria (2013)== | ==IWG-MRT & ECNM consensus response criteria (2013)== | ||
# Gotlib J, Pardanani A, Akin C, Reiter A, George T, Hermine O, Kluin-Nelemans H, Hartmann K, Sperr WR, Brockow K, Schwartz LB, Orfao A, Deangelo DJ, Arock M, Sotlar K, Horny HP, Metcalfe DD, Escribano L, Verstovsek S, Tefferi A, Valent P. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood. 2013 Mar 28;121(13):2393-401. Epub 2013 Jan 16. [http://www.bloodjournal.org/content/121/13/2393.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23325841 PubMed] | # Gotlib J, Pardanani A, Akin C, Reiter A, George T, Hermine O, Kluin-Nelemans H, Hartmann K, Sperr WR, Brockow K, Schwartz LB, Orfao A, Deangelo DJ, Arock M, Sotlar K, Horny HP, Metcalfe DD, Escribano L, Verstovsek S, Tefferi A, Valent P. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood. 2013 Mar 28;121(13):2393-401. Epub 2013 Jan 16. [http://www.bloodjournal.org/content/121/13/2393.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23325841 PubMed] | ||
− | |||
− | |||
− | |||
− | |||
[[Category:Chemotherapy regimens]] | [[Category:Chemotherapy regimens]] | ||
[[Category:Malignant hematology regimens]] | [[Category:Malignant hematology regimens]] | ||
+ | [[Category:Systemic mastocytosis regimens]] |
Revision as of 23:44, 29 April 2017
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
7 regimens on this page
13 variants on this page
|
Aggressive systemic mastocytosis (ASM)
Allogeneic hematopoietic cell transplant
back to top |
To our knowledge, only retrospective analyses have been published.
References
- Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S, Shanley R, Hogan WJ, Perales MA, Shore T, Baurmann H, Stuart R, Gruhn B, Doubek M, Hsu JW, Tholouli E, Gromke T, Godley LA, Pagano L, Gilman A, Wagner EM, Shwayder T, Bornhäuser M, Papadopoulos EB, Böhm A, Vercellotti G, Van Lint MT, Schmid C, Rabitsch W, Pullarkat V, Legrand F, Yakoub-Agha I, Saber W, Barrett J, Hermine O, Hagglund H, Sperr WR, Popat U, Alyea EP, Devine S, Deeg HJ, Weisdorf D, Akin C, Valent P. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol. 2014 Oct 10;32(29):3264-74. Epub 2014 Aug 25. link to original article PubMed
Cladribine (Leustatin)
back to top |
Regimen #1
Study | Evidence |
Kluin-Nelemans et al. 2003 | Pilot, <20 patients reported |
Chemotherapy
- Cladribine (Leustatin) 0.13 mg/kg IV over 2 hours once per day on days 1 to 5
Supportive medications
- Clemastine (Tavist) 1 to 2 mg IV prior to Cladribine (Leustatin)
- Dexamethasone (Decadron) 5 mg IV prior to Cladribine (Leustatin)
- Fluconazole (Diflucan) (dose not specified)
- Co-trimaxazole (dose not specified)
- Valacyclovir (Valtrex) (dose not specified) "in some patients"
4 to 6-week cycle for 6 cycles
Regimen #2
Study | Evidence |
Lim et al. 2009 | Retrospective |
This is a retrospective series.
Chemotherapy
- Cladribine (Leustatin) 5 mg/m2 or 0.13 to 0.17 mg/kg IV over 2 hours once per day on days 1 to 5
Median number of treatment cycles was 3 (range 1 to 9)
Regimen #3
Study | Evidence |
Hermine et al. 2010 | Retrospective |
Chemotherapy
- Cladribine (Leustatin) 0.15 mg/kg IV over 2 hours or SC once per day on days 1 to 5
4 to 12-week cycle for 1 to 6 cycles
References
- Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van 't Wout JW, Verhoef G, Gerrits WB, van Dobbenburgh OA, Pasmans SG, Fijnheer R. Cladribine therapy for systemic mastocytosis. Blood. 2003 Dec 15;102(13):4270-6. Epub 2003 Aug 21. link to original article contains verified protocol PubMed
- Retrospective: Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009 Dec;84(12):790-4. link to original article PubMed
- Abstract: Retrospective: Hermine, Olivier, Hirsh, Isabelle, Damaj, Gandhi, Granpeix, Catherine, Barete, Stephane, Suarez, Felipe, Chansderis, Olivia, Ghez, David, Delarue, Richard, Lanternier, Fanny, Deau, Benedicte, Coignard, Helene, Fraitag, Sylvie, Canioni, Danielle, Casassus, Philippe, Dubreuil, Patrice, Lortholary, Olivier. Long Term Efficacy and Safety of Cladribine In Adult Systemic mastocytosis: a French Multicenter Study of 44 Patients. ASH Annual Meeting Abstracts 2010 116: 1982 link to original abstract
- Update: Retrospective: Barete S, Lortholary O, Damaj G, Hirsch I, Chandesris MO, Elie C, Hamidou M, Durieu I, Suarez F, Grosbois B, Limal N, Gyan E, Larroche C, Guillet G, Kahn JE, Casassus P, Amazzough K, Coignard-Biehler H, Georgin-Lavialle S, Lhermitte L, Fraitag S, Canioni D, Dubreuil P, Hermine O. Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood. 2015 Aug 20;126(8):1009-16; quiz 1050. Epub 2015 May 22. link to original article PubMed
Dasatinib (Sprycel)
back to top |
Regimen
Study | Evidence |
Verstovsek et al. 2008 | Phase II |
Only 9 of 67 patients studied had ASM; 18 has ISM and 6 had SM-AHNMD.
Chemotherapy
- Dasatinib (Sprycel) 70 mg PO BID or 140 mg PO once per day
Supportive medications
- Hematopoietic growth factors at investigator discretion
28-day cycles until disease progression or intolerable toxicity
References
- Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D, Kantarjian H. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res. 2008 Jun 15;14(12):3906-15. link to original article contains verified protocol PubMed
Imatinib (Gleevec)
back to top |
Regimen #1
Study | Evidence |
Vega-Ruiz et al. 2009 | Phase II |
Chemotherapy
- Imatinib (Gleevec) 400 mg PO once per day, increased by 200 mg every month to a maximum of 800 mg PO once per day
Supportive medications
- Hematopoietic growth factors at investigator discretion
Continued until disease progression or unacceptable toxicity.
Regimen #2
Study | Evidence |
Droogendijk et al. 2006 | Phase II, <20 pts reported |
Chemotherapy
- Imatinib (Gleevec) 400 mg PO once per day
Supportive medications
- Prednisone (Sterapred) 15 mg PO BID for first 2 weeks of treatment
Up to 6 month course
References
- Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC, Tefferi A. Imatinib for systemic mast-cell disease. Lancet. 2003 Aug 16;362(9383):535-6. link to original article PubMed
- Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer. 2006 Jul 15;107(2):345-51. link to original article contains verified protocol PubMed
- Retrospective: Pagano L, Valentini CG, Caira M, Rondoni M, Van Lint MT, Candoni A, Allione B, Cattaneo C, Marbello L, Caramatti C, Pogliani EM, Iannitto E, Giona F, Ferrara F, Invernizzi R, Fanci R, Lunghi M, Fianchi L, Sanpaolo G, Stefani PM, Pulsoni A, Martinelli G, Leone G, Musto P. Advanced mast cell disease: an Italian Hematological Multicenter experience. Int J Hematol. 2008 Dec;88(5):483-8. Epub 2008 Nov 26. link to original article PubMed
- Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quintás-Cardama A, Luthra R, Kantarjian HM, Verstovsek S. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res. 2009 Nov;33(11):1481-4. Epub 2009 Feb 3. link to original article contains verified protocol PubMed
- Retrospective: Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009 Dec;84(12):790-4. link to original article PubMed
Interferon alfa-2b (Intron-A)
back to top |
Regimen
Study | Evidence |
Casassus et al. 2002 | Phase II |
Doses were escalated based on tolerance.
Chemotherapy
- Interferon alfa-2b (Intron-A) as follows:
- Week 1: 1 million units (MU) SC once per day
- Week 2: 3 MU SC once per day
- Weeks 3 & 4: 3 MU/m2 SC once per day
- Week 5 onwards: 5 MU/m2 SC once per day
6-month course, continued at physician's and patient's discretion
References
- Casassus P, Caillat-Vigneron N, Martin A, Simon J, Gallais V, Beaudry P, Eclache V, Laroche L, Lortholary P, Raphaël M, Guillevin L, Lortholary O. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol. 2002 Dec;119(4):1090-7. link to original article contains verified protocol PubMed
- Retrospective: Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009 Dec;84(12):790-4. link to original article PubMed
Midostaurin (Rydapt)
Midostaurin (Rydapt) for aggressive systemic mastocytosis
Nilotinib (Tasigna)
back to top |
Regimen
Study | Evidence |
Hochhaus et al. 2015 | Phase II |
Chemotherapy
- Nilotinib (Tasigna) 400 mg PO BID
28-day cycles until disease progression or unacceptable toxicity
References
- Hochhaus A, Baccarani M, Giles FJ, le Coutre PD, Müller MC, Reiter A, Santanastasio H, Leung M, Novick S, Kantarjian HM. Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study. J Cancer Res Clin Oncol. 2015 Nov;141(11):2047-60. Epub 2015 May 23. link to PMC article contains verified protocol PubMed
Response criteria
IWG-MRT & ECNM consensus response criteria (2013)
- Gotlib J, Pardanani A, Akin C, Reiter A, George T, Hermine O, Kluin-Nelemans H, Hartmann K, Sperr WR, Brockow K, Schwartz LB, Orfao A, Deangelo DJ, Arock M, Sotlar K, Horny HP, Metcalfe DD, Escribano L, Verstovsek S, Tefferi A, Valent P. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood. 2013 Mar 28;121(13):2393-401. Epub 2013 Jan 16. link to original article PubMed